To develop prognosis tests to assess the risk of liver related morbidity, in particular, to predict the risk of progression from benign fatty liver towards NASH and advanced liver diseases.SOLUTION: This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis), or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification, for studying drugs, monitoring patient, and assigning an appropriate treatment.SELECTED DRAWING: None
GENE SIGNATURES OF INFLAMMATORY DISORDERS THAT RELATE TO THE LIVER